Navigation Links
Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008
Date:5/7/2008

(1,888)

Total other income (expense) (5,273) (5,922)

Income before income taxes 8,702 6,567

Income taxes 3,078 2,364

Net income $5,624 $4,203

Income per share data:

Basic:

Net income per share $0.38 $0.29

Weighted average shares

outstanding 14,690 14,438

Diluted:

Net income per share $0.38 $0.28

Weighted average shares

outstanding 14,975 14,842

Kendle International Inc.

Selected Balance Sheet and Other Information

(In thousands)

(Unaudited)

March 31, 2008 December 31, 2007

Cash, cash equivalents and

marketable securities (including

restricted cash) $32,037 $46,356

Receivables, net of advance billings 79,655 57,148

Convertible notes 200,000 200,000

Segment Information:

Three Months Ended

March 31,

2008 2007

Early Stage:

Net Service Revenues $5,638 $5,411

Operating Income 386 542

Late Stage:

Net Service Revenues $104,779 $88,440

Operating Income 24,666
'/>"/>

SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Kendle Promotes Simon S. Higginbotham to President; Appoints Alan J. Boyce as Chief Marketing Officer
2. Kendle Delivers Strong Growth in Revenues, New Business Authorizations and Operating Margin for Full-Year 2007; Announces Guidance for 2008
3. Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast
4. Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion
5. Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007
6. Kendle Appoints Ken Hintze, PhD, Vice President, Global Clinical Safety & Pharmacovigilance
7. Kendle Executive Dennis Hurley, DrSc to Present Keynote Address at DIA Latin American Congress 2007
8. Four Rivers Software Systems Delivers TMS WorkGroup 2008.3.3
9. New York Cigarette Tax Increase Delivers Victory for Kids and Taxpayers
10. FEW Announces Legislative Goals for Remainder of 110th Congress; Delivers Fact Sheets to Legislators
11. Ingenuity Systems Delivers Key Milestones in FDA Collaboration to Facilitate Genomic Data Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...Research(TM), a revolutionary,biometric media res...urement,announced today the appointment of three...earch and development, business strategy and marke..., who deliver a combined 60 years of experience,...nd Vice President of,Strategy; Dr. Ravi Kothuri a...
(Date:11/21/2008)... Texas M. D. Anderson Cancer Center marked the beg...st cancer in Panama through the Partnership for Br... today at an event with Laura Bush, the First Lady...ijos, the First Lady of Panama. , Joining M. D...nt of State and Susan G. Komen for the Cure who ar...
(Date:11/21/2008)...Minnesotans who successfully,quit smoking will re...ion at,the Minnesota Wild game on November 24 at ...ants in The QuitCash Challenge, a new stop-smoking...(R) Services. , The grand prize winner will...l get $1,000 gift cards from Gander Mountain. , ...
(Date:11/21/2008)...entions in computerized brain,training may help p...d fuller,lives, said Jeff Zimman, Chairman of Pos... at the annual Technology Innovators Conference in...nal Center for Technology Innovation to,promote i... Zimman said cognitive training programs can a...
Breaking Medicine News(10 mins):Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research extends to Panama 2Health News:Lucky Quitters to Receive Big Money in Stop-Smoking Contest 2Health News:New Applications for Cognitive Training 2
...The Weizmann Institute of Science’s researchers ha...e apparently well preserved. The Proceedings of th...hed the reports of the scientists. The fossil DNA ...lation dynamics, evolution, diets and diseases, an...
...Professor Timothy Lohman and colleagues from Unive...porosis International// that supplementing post-me...r exercise makes their bone fit and prevents bone ...sity (BMD) which highly reduces the risk of develo...
...A vaccine called RotaTeq for rotavirus has been ap...o vomiting and diarrhea claims the lives of about ...one of the largest clinical trials in history, Mer...ccine on more than 70,000 children that showed it ...
...Breast Tumor Cells may develop due to changes in t...er pregnancy, according to a paper by McDaniel. Th...f The American Journal of Pathology. // The stage...ution dictate drastic changes in the tissues of th...
Other Medicine News:
(Date:11/20/2008)...RSIDE, Calif., Nov. 20 Milk. It do... than originally thought. After years of,research...peptides found in,cow,s milk that stimulate the b... To view the Multimedia News Release, go to:, http..., While developing new cancer therapies, th...
(Date:11/20/2008)...YORK, Nov. 20 Clinical data from a...35th Annual Veith Symposium shows DVT,treatment w... Bacchus,Vascular, Inc. (Santa Clara, CA) success...n about 20 minutes. , This technique, calle...es,blood flow more quickly and safely than curren...
(Date:11/19/2008)...SAND OAKS, Calif., Nov. 19 /PRNewswire-FirstCall/ ...keda Oncology Company, a subsidiary of,Takeda Pha...ounced that,enrollment in the Phase 3 MONET1 tria...ith paclitaxel and carboplatin for the first-line ...(NSCLC) has been temporarily suspended,following ...
(Date:11/19/2008)...RK, Del., Nov. 19 Isogen, a contra... sterile filling, today announced the first,phase...en was founded to,specifically address the proces...ated with the $2 billion highly-niched, low-volume...ing market segment. , Companies can invest ...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Isogen Launches Major New Facility to Address Global Biopharma Demand 2Cardiome Reports First Quarter Results 19236 1Cardiome Reports First Quarter Results 19236 2Cardiome Reports First Quarter Results 19236 3Cardiome Reports First Quarter Results 19236 4Cardiome Reports First Quarter Results 19236 5PharmAthene Reports First Quarter 2008 Financial Results 5367 1PharmAthene Reports First Quarter 2008 Financial Results 5367 2PharmAthene Reports First Quarter 2008 Financial Results 5367 3PharmAthene Reports First Quarter 2008 Financial Results 5367 4PharmAthene Reports First Quarter 2008 Financial Results 5367 5PharmAthene Reports First Quarter 2008 Financial Results 5367 6PharmAthene Reports First Quarter 2008 Financial Results 5367 7Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 1Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 2Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 3Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 4Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 5Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 6Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 7Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 8Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 9Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 10Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 11Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 12Particle Sciences Adds Additional Clean Room Space 5363 1
...0, 2007 - People with a,class of rare genetic diso...ath can be successfully treated with drugs, says a...edicine and Lucile,Packard Children,s Hospital., T...r study that,prompt diagnosis coupled with a rapid...mproves the survival rates of people with,the cond...
...he Treatment of Ischemic,Stroke, GLASGOW, Scotland...ogical Technologies, Inc. (NTI) announced today th...clinical trials of,ancrod and updates on the clini...rinex (ancrod), for the treatment of acute,ischemi...ss in,Glasgow, Scotland in the United Kingdom. Vip...
Other Medicine Technology:Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard,Researcher 2Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard,Researcher 3Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard,Researcher 4Presentations at 2007 European Stroke Congress Highlights New,Direction for Viprinex (ancrod) 2Presentations at 2007 European Stroke Congress Highlights New,Direction for Viprinex (ancrod) 3Presentations at 2007 European Stroke Congress Highlights New,Direction for Viprinex (ancrod) 4
..., real-time thermal cycler used for identifying DN...ing much of the testing process, and making each r...fastest, easiest to use, and most flexible system ... accurate and consistent test results in as little...
...ection System is a high-throughput real-time PCR s...quences. An Automation Accessory combined with 384...lly suited to meet the high-throughput requirement...ns include gene expression quantitation and the de...
Sealing Mat for 384-well, Square Well Plates Available Sterile
Sealing Mat for 384-well PCR Plate, Natural
Medicine Products: